The firm will offer up to 12,030,218 common shares for Keystone Capital Partners to sell and is expecting to net around $2.1 million in gross proceeds.

The Tokyo-based biotech firm expects RV-001 to be able to alter light sensitivity for patients with limited or no vision regardless of genotype.

The foundation hopes to put the funds toward two clinical programs in blood cancers and one preclinical project in solid tumors.